GLP1’s, Ozempic and Eating Disorders: What Patients and Families Should Know

GLP-1 receptor agonists — medications like Ozempic, Wegovy, Zepbound, and Mounjaro — represent a genuine advance in medicine. For many people living with obesity or type 2 diabetes, these medications have meaningfully improved health outcomes, reduced cardiovascular risk, and provided relief from conditions that have been difficult to treat for decades.

This article is not a warning against those medications. They are medically appropriate for many people.

But for people with active eating disorder symptoms — or a history of disordered eating — the picture is more complex. The relationship between Ozempic and eating disorders is an emerging clinical conversation that patients, families, and prescribers need to have. And right now, in the rush of prescriptions and cultural enthusiasm, that conversation is often not happening.

How GLP-1 Medications Work

GLP-1 (glucagon-like peptide-1) receptor agonists work primarily by:

• Stimulating insulin secretion in response to food intake
• Suppressing glucagon, which reduces glucose production in the liver
• Slowing gastric emptying, so food moves more slowly through the digestive system
• Acting on appetite-regulating centers in the brain to reduce hunger signals and increase satiety

The result, for many patients, is a significant reduction in appetite — sometimes described as “food noise” going quiet for the first time. For patients who have struggled for years with persistent hunger and difficult-to-manage weight, this can feel like freedom.

For someone with a history of restriction, however, that same suppression of hunger signals may not be relief. It may be destabilization.

The Risk Landscape for People With Eating Disorder History

Clinical eating disorder specialists have begun raising concerns about GLP-1 use in patients with eating disorder histories. While large-scale controlled research is still limited, the clinical rationale is well-grounded.

Restriction and Relapse

For someone in recovery from anorexia nervosa or restrictive eating, a medication that suppresses appetite and makes food feel unnecessary can reinforce exactly the behaviors recovery has worked to undo. The absence of hunger — which many patients with restriction history are already learning to distrust — can feel like permission to eat less.

Eating disorder recovery often involves learning to honor hunger cues, eat adequate quantities, and rebuild a trusting relationship with physical signals. A medication that pharmacologically suppresses those signals can undermine that work, even in patients who are genuinely committed to recovery.

Compensatory Behaviors and Binge-Purge Cycles

For individuals with bulimia nervosa or binge eating disorder, the picture is more nuanced and potentially paradoxical. While GLP-1s may reduce binge frequency in some patients, they may also interact with established compensatory patterns — or, if episodes do occur, create more shame and distress in a way that accelerates the cycle.

Early clinical case reports have noted patients using GLP-1-induced restriction to compensate, or experiencing significant guilt and relapse of purging behaviors when the medication’s effects allowed eating that felt “too much.”

Body Image and Weight Obsession

GLP-1 medications, particularly when prescribed for weight loss, are embedded in a cultural conversation about body size. For patients who already struggle with body dysmorphia or who have an unhealthy relationship with weight, the focus on the scale that often accompanies GLP-1 use can reinforce harmful thought patterns — even when the weight change itself is medically appropriate.

As researchers including Dr. Jena Shaw Tronieri and others at eating disorder specialty centers have noted: weight-focused framing of GLP-1 treatment, without adequate psychological support, can be destabilizing for patients with eating disorder histories.

The Screening Gap

Currently, there is no standardized protocol requiring eating disorder screening before GLP-1 prescription. These medications are being prescribed at high volume by primary care physicians, endocrinologists, telehealth platforms, and weight loss clinics — many of which do not routinely assess for eating disorder history.

A 2023 review published in the *International Journal of Eating Disorders* highlighted this screening gap as a significant clinical concern, calling for eating disorder assessment prior to and during GLP-1 treatment for at-risk patients. The Eating Disorders Coalition and several leading eating disorder treatment organizations have also published guidance calling for integrated care when GLP-1s are prescribed to patients with known or suspected eating disorder history.

Warning Signs to Watch For

If you or someone you care for is currently taking a GLP-1 medication, here are the warning signs that an eating disorder may be emerging or returning:

• Restricting beyond what the medication explains — eating very little by choice, not just reduced appetite
• Return of rituals — food rules, compensatory behaviors, restrictive thinking patterns that had been in remission
• Intense focus on weight loss beyond the therapeutic goal — distress when weight loss slows, escalating desire to restrict further
• Physical symptoms of under-nutrition — fatigue, dizziness, hair loss, loss of menstrual period, brain fog
• Hiding behaviors — eating alone, not disclosing actual food intake to medical providers
• Increased preoccupation with food, calories, or body size — rather than the decreased food noise that GLP-1s are intended to produce
• Mood changes — new or worsening anxiety, depression, or irritability, particularly around food or meals
• Purging behaviors — vomiting, laxative use, or excessive exercise used alongside the medication

If you are in recovery and have been prescribed a GLP-1 medication, please disclose your eating disorder history to your prescriber. This is not information you are obligated to share, but it is clinically relevant — and it changes how your care should be managed.

────────────────────────────────────────────────────────────

What Appropriate Care Looks Like

For patients with eating disorder history who are being considered for GLP-1 medications, best-practice care includes:

• Eating disorder screening prior to prescription (instruments like the EDE-Q or SCOFF take minutes to administer)
• Coordination with an eating disorder therapist or dietitian throughout GLP-1 treatment
• Regular monitoring — not just of weight and metabolic markers, but of psychological state, food behaviors, and eating disorder symptom recurrence
• Careful framing of the medication’s purpose — focused on metabolic health, not primarily on weight or body size
• Clear communication between prescribers and mental health/eating disorder providers

This is not about withholding beneficial treatment. It is about providing it safely — with the wraparound support that makes outcomes better for everyone.

• eating disorder providers

This is not about withholding beneficial treatment. It is about providing it safely — with the wraparound support that makes outcomes better for everyone.

────────────────────────────────────────────────────────────

For Families: How to Support a Loved One

If someone you love has an eating disorder history and has been prescribed a GLP-1, you don’t need to be alarmist — but staying connected and attentive is appropriate.

Gently encourage them to be honest with their prescriber about their history. If you notice warning signs of relapse, name what you’re observing with compassion, not accusation. And know that specialized eating disorder treatment is available if things escalate.

You might say: *”I’ve noticed you seem anxious around eating lately. I want to make sure you’re getting the support you need. Can we talk about it?”*

────────────────────────────────────────────────────────────

A Note on the Broader Conversation

The GLP-1 conversation will continue to evolve. These medications are being studied for an expanding range of indications, and the clinical literature on their interaction with eating disorders is actively developing. What we know now is enough to warrant thoughtful, individualized care — not blanket restriction, and not uncritical enthusiasm.

Eating disorders are complex, serious illnesses. They deserve the same evidence-based rigor applied to any other medical condition. As GLP-1 use expands, the eating disorder field is working to ensure that patients with these vulnerabilities are not left behind.

Learn more about evidence-based treatment approaches at Remedy Therapy Center for Eating Disorders.

────────────────────────────────────────────────────────────

Specialized Help Is Available

If GLP-1 use has triggered or worsened eating disorder symptoms, specialized care can help. Early intervention matters — the sooner disordered eating patterns are addressed, the better the outcomes.

Remedy Therapy Center for Eating Disorders offers residential, PHP, IOP, and outpatient programs for adult women, with a full clinical team that includes therapists, registered dietitians, and medical staff with expertise in eating disorder recovery. We are JCAHO accredited, accept BCBS, UHC, and Aetna insurance, and serve women 18 and older at our campuses in Jensen Beach and Stuart, Florida.

Treatment modalities include Individual Therapy, CBT, DBT, Body Image Therapy, Trauma Resolution Therapy (EMDR and ART), Nutritional Programming, and Medical Oversight — a comprehensive approach that addresses every dimension of eating disorder recovery

📞 Call (772) 677-9993 — we’re available 24/7.

If you’re not sure whether what you’re experiencing rises to the level of “needing treatment,” call anyway. That’s what we’re here for.